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OBJECTIVES This retrospective study was performed to provide data on ventricular tachycardias (VT) with
a cycle length longer than the initially programmed tachycardia detection interval (TDI) in
patients with implantable cardioverter defibrillators (ICDs).
BACKGROUND It has been clinical practice to program a safety margin of 30 to 60 ms between the slowest
spontaneous or inducible VT and the TDI.
METHODS Baseline characteristics of 659 consecutive patients with ICDs were prospectively; follow-up
information was retrospectively collected.
RESULTS During a mean follow-up of 31 6 23 months, 377 patients (57.2%) had at least one recurrent
VT or ventricular fibrillation; 47 patients (7.1%) suffered 61 VTs above the TDI. The risk of
a VT above the TDI ranged between 2.7% and 3.5% per year during the first four years after
ICD implantation. The difference between the cycle length of the slowest VT before ICD
implantation, spontaneous or induced, and the first VT above TDI was 108 6 58 ms.
Fifty-four VTs (88.5%) above the TDI were associated with significant clinical symptoms
(angina or palpitation 63.9%, heart failure 6.6% and syncope 8.2%). Six patients (9.8%) had
to be resuscitated. Kaplan-Meyer analysis identified New York Heart Association class II or
III (p 5 0.021), ejection fraction , 0.40 (p 5 0.027), spontaneous (p , 0.001) or inducible
(p , 0.001) monomorphic VTs and the use of class III antiarrhythmic drugs (amiodarone,
p , 0.001; sotalol, p 5 0.004) as risk predictors of VTs above the TDI. The risk of recurrent
VTs above TDI was 11.8%, 12.5% and 26.6% during the first, second and third year after first
VT above TDI, respectively.
CONCLUSIONS The risk of VTs above the TDI is significantly increased in some patients, and many VTs
above TDI cause significant clinical symptoms. A larger safety margin between spontaneous
or inducible VTs and the TDI seems to be necessary in selected patients. This is in conflict
with an increased risk of inadequate episodes and demands highly specific and sensitive
detection algorithms in these patients. (J Am Coll Cardiol 2000;36:557–65) © 2000 by the
American College of Cardiology
Implantable cardioverter defibrillators (ICDs) terminate
ventricular tachycardias (VT) and ventricular fibrillation
(VF) with high success rates and prolong lives in patients at
high risk of ventricular tachyarrhythmias (1–6). Since the
first ICD implantation in 1980 by Mirowski (1), program-
ming practice has changed considerably due to technical and
scientific progress. Primary detection criterion for VTs has
always been tachycardia detection interval (TDI). Current
practice relates the TDI to the slowest spontaneous or
inducible VT. Usually, a safety margin of 30 to 60 ms
between the slowest spontaneous or inducible VT and the
TDI has been programmed (7). Until a few years ago, a
TDI of 280 to 330 ms was programmed in patients after
survived cardiac arrest without spontaneous or inducible
monomorphic VTs (1). Because a considerable proportion
of patients with structural heart disease develop monomor-
phic VTs during follow-up and many VF episodes develop
from monomorphic VTs, ICDs are currently programmed
empirically as a two-zone device with a VT zone starting at
170–190 beats/min and VF zone starting between 200 and
220 beats/min, even if no VT has been documented or
induced (8).
The specificity of detection has been enhanced by addi-
tional criteria such as stability and onset of VT cycle length
(CL) (9,10), QRS width of sensed electrograms (11) and in
case of dual-chamber ICDs, atrioventricular dissociation
(12–14). Nondetection of VTs or therapy delay, due to
undersensing or algorithms that increase specificity of VT
detection, has been described (8,9,15,16). In contrast, only
single cases of VTs above the initially programmed TDI
have been reported (17), and the incidence and clinical
significance of these VTs remain to be defined.
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In this study, the occurrence of VTs above TDI and their
clinical impact was retrospectively analyzed in order to
evaluate current programming practice and modify it, if
necessary.
METHODS
Definitions. The occurrence of a VT, detected by the
ICD, was assumed, if stored tachycardia CLs were short
(,250 ms), or decreased suddenly at the onset of the
tachycardia and were stable, or the morphology of stored
electrograms was different from the morphology during
sinus rhythm or antitachycardia pacing successfully termi-
nated the tachyarrhythmias.
A VT above TDI was assumed, if at least a one-lead
electrocardiogram (ECG) documentation of the VT was
available. Nonsustained VTs above the TDI were not
included. Few VTs (9 of 61) above TDI were gathered from
ICD memory data. In these cases, the VT was symptomatic
and lasted long enough for the patient to be hospitalized
because of the VT, but the VT accelerated before an
external ECG documentation could be obtained. All ECGs
of VTs above TDI were reviewed by at least two cardiolo-
gists. If there was doubt about the origin of the tachycardia,
it was not classified as ventricular.
ICD programming. Programming practice has changed
during the last decade due to technical and scientific
progress. Coherence in programming strategy was achieved
in our clinic by programming rules layed down in an ICD
handbook, which the implanting physician had to follow.
We have always considered the spontaneous or inducible
VT for ICD programming and added a safety margin
between 30 and 60 ms to the slowest sustained VT. In case
no VT was documented or induced, the programming
strategy has changed during recent years. Until 1994, we
used a one-zone shock-only programming in these patients,
if anamnestic details such as syncope did not suggest
monomorphic VTs. The TDI was programmed empirically
between 180 and 220 beats/min depending on the patient’s
left ventricular ejection fraction (EF). In recent years, we
have always programmed two zones with a VT zone starting
at 170 to 190 beats/min and a VF zone between 200 and
220 beats/min if no VT was documented, because several
trials suggest that patients with structural heart disease tend
to have VF initiated by VTs, even if no VTs could be
documented (18).
Patients. Baseline characteristics of 659 consecutive pa-
tients who received ICDs at our Institution (University of
Mu¨nster) between July 1988 and August 1998 were pro-
spectively collected in an ICD database. Indications for
ICD implantation were survived cardiac arrest or polymor-
phic VT in 273 patients (41.4%), monomorphic VT in 188
(28.5%), monomorphic VT and VF in 141 (21.4%), non-
sustained VT in 24 (3.6%) and syncope plus inducible VTs
in 34 (5.2%; Table 1). Prophylactic indications for ICD
implantation were excluded from analysis.
All patients underwent coronary angiography and pro-
grammed ventricular stimulation (PVS) off antiarrhythmic
therapy or on amiodarone before ICD implantation, at
discharge and after any change of antiarrhythmic medica-
tion. In case of amiodorone control, stimulation was per-
formed after a loading phase of 10 to 15 g of amiodarone.
Electrophysiological study before and after ICD implanta-
tion was performed according to the same protocol. Pro-
grammed ventricular stimulation was performed at three
basic CLs with up to three extra stimuli until the protocol
was finished or VF or very fast VT was induced, which
required cardioversion (19). In 299 patients (45.4%), a
single detection zone with shock therapy, and in 360
(54.6%), at least two detection zones and antitachycardia
pacing were programmed. The mean TDI was 376 6 55
beats/min.
Variables for risk prediction of VTs, shocks and VTs
below the detection rate were prospectively collected in an
ICD database and included patients’ characteristics such as
heart disease, New York Heart Association (NYHA) class
at the time of implantation, history of decompensation,
previous antiarrhythmic interventions, results of left and
right heart catheter, spontaneous VTs, results of PVS,
baseline electrocardiograms at implantation as well as hos-
pital discharge data and antiarrhythmic medication at dis-
charge and during follow-up.
Follow-up. Patients visited the ICD outpatient clinic rou-
tinely every three months and were encouraged to schedule
additional visits, if the first shock, clusters of shocks or
syncope occurred. They were questioned about extraordi-
nary events such as extra hospital admissions for cardiac
events, and medical reports of these events were obtained. If
patients died, we routinely performed a postmortem inter-
rogation of the device. No patient has been lost to follow-
up. However, patients who were no longer followed at our
or an affiliated clinic and patients who underwent ICD
explantation for various reasons were censored at the last
visit at our or an affiliated clinic. Chart reviews and printouts
were checked for VTs above the programmed TDI, causes
or permissive factors and measures taken to avoid recur-
rences. Mean follow-up time was 31 6 26 months.
Statistical analysis. Mean 6 standard deviation was used
for continuous variables with normal distribution and t test
was applied to compare means. Median and range or 95%
Abbreviations and Acronyms
CL 5 cycle length
ECG 5 electrocardiogram
EF 5 ejection fraction
ICD 5 implantable cardioverter defibrillator
NYHA 5 New York Heart Association
PVS 5 programmed ventricular stimulation
TDI 5 tachycardia detection interval
VF 5 ventricular fibrillation
VT 5 ventricular tachycardia
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confidence interval was used to describe continuous vari-
ables without normal distribution and Mann Whitney U
test was applied to compare ranks. Frequency distributions
between groups of patients were tested with the chi square
test. A two-tailed p value of equal or less than 0.05 was
regarded as significant. The probability of major events was
calculated according to the Kaplan-Meier method and
measured from the date of implantation, first VT or first VT
above TDI to the event (20). Differences between pairs of
actuarial curves were tested by Mantel-Haenszel log-rank
test. Cox regression analysis was performed on patients’
baseline characteristics to investigate the influence of differ-
ent variables. For continuous variables, the hazard for an
increase of one in the value of the covariate was calculated
from the regression coefficient b: exp(b). For binary vari-
ables, the hazard ratio for the presence of a certain charac-
teristic was calculated as exp(b), where b is the regression
coefficient. Statistical analysis was done with SPSS (Statis-
tical Package for Social Sciences, version 6.0) for Windows.
RESULTS
Incidence of tachycardias below the detection rate. Pa-
tients’ baseline characteristics are presented in Table 1.
Table 1. Baseline Characteristics of Patients
All
Patients
With VTs
Above TDI
p
Value
Patients With VT
Above TDI
N 659 47 330
Follow-up (months) 31 6 23 28 6 23 NS 35 6 23
Underlying cardiac disease
CAD/MI 60.4% 70.2% NS 60.0%
DCM 18.8% 17.0% NS 23.0%
Normal heart 6.5% 2.1% NS 4.5%
ARVD 5.0% 4.3% NS 5.8%
Torsades 1.5% 0% NS 1.2%
Valvular disease 4.9% 6.4% NS 3.0%
Other 2.9% 0% NS 2.4%
Infarction 42.0% 51.1% NS 43.3%
Aneurysm 17.1% 21.3% NS 20.0%
Functional classification
NYHA I 21.5% 10.6% NS 17.3%
NYHA II 47.3% 51.1% NS 47.6%
NYHA III 31.1% 38.3% NS 35.2%
Prior decompensation 14.4% 19.1% NS 17.6%
Ejection fraction 0.43 6 0.18 0.39 6 0.15 NS 0.41 6 0.17
Afib/Aflu* 22.9% 23.9% NS 21.9%
Pacemaker 3.3% 2.1% NS 4.8%
QRS duration (ms)† 106 6 54 110 6 32 NS 107 6 29
QT duration (ms)† 393 6 54 402 6 56 NS 397 6 58
Presenting arrhythmia
VF/pVT 41.4% 19.1% 33.3%
mVT 28.5% 46.8% 0.049‡ 35.5%
mVT 1 VF 21.4% 29.8% 26.4%
nsVT 3.6% 2.1% NS 1.5%
Syncope 5.2% 2.1% NS 3.3%
Slowest VT CL (ms) 340 6 50 NS 355 6 40
Baseline PVS
Inducible VT/VF 68.0% 91.5% — 75.5%
Inducible mVT 55.5% 89.1% ,0.002 66.0%
Induced VT CL (ms) 286 6 81 299 6 65 NS 294 6 84
Discharge test
Induced VT CL (ms) 288 6 78 315 6 70 NS 292 6 79
Detection interval (ms) 348 6 58 376 6 55 0.045 358 6 62
Discharge medication
Class I-AA 2.0% 4.3% NS 3.0%
Beta-blocker 25.8% 23.4% NS 21.8%
Sotalol 9.3% 17.0% ,0.001 7.9%
Amiodarone 7.1% 19.1% ,0.001 5.8%
Digitalis 59.5% 79.1% NS 76.7%
AA 5 antiarrhythmic agent; Afib 5 atrial fibrillation; Aflu 5 atrial flutter; ARVD 5 arrhythmogenic right ventricular disease; CAD 5 coronary artery disease; CL 5 cycle
length; DCM 5 idiopathic dilated cardiomyopathy; mVT 5 monomorphic ventricular tachycardia; MI 5 myocardial infarction; NYHA 5 New York Heart Association;
nsVT 5 nonsustained ventricular tachycardia; PVS 5 programmed ventricular stimulation; TDI 5 tachycardia detection interval; VF 5 ventricular fibrillation; VT 5 ventricular
tachycardia.
*Chronic or intermittent; †patients with pacemakers not included; ‡chi-square test.
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Three hundred seventy-seven patients (57.2%) had a recur-
rent VT or VF. The per-year risk to suffer a first VT
decreased during the first four years and was 59.2%, 23.9%,
13.7% and 8.3% in the first, second, third and fourth year
after ICD implantation, respectively. Forty-seven patients
(7.1%) suffered 61 VTs below the detection rate. Forty-
eight VTs above TDI (78.8%) were documented with
12-channel ECGs, four (6.6%) during holter monitoring
and nine (14.8%) could be gathered from ICD memory
data. In these patients, tachycardia lasted long enough that
hospital admission was initiated, but the VTs accelerated
into the programmed detection zone before an ECG could
be obtained. The CLs of VTs above TDI were 441 6
60 ms. The difference between the VT above TDI and the
slowest VT, spontaneous or induced, before ICD implan-
tation was 108 6 58 ms. The difference between the initially
programmed TDI and the first VT above TDI was 39 6
34 ms.
The risk of a VT above TDI was about 3% (range 2.7%
to 3.5% per year) and remained fairly constant during the
first four years after ICD implantation (Table 2, Fig. 1).
The relative risk for a first VT being a VT above TDI,
therefore, increased with time (see risk of any first VT), and
was 5.1%, 11.3%, 25.5% and 32.5% during the first, second,
Figure 1. Risk of VTs above the programmed tachycardia detection interval.
Table 2. Kaplan Meyer Analysis for Major Events
Risk Per Year (%) 1st 2nd 3rd 4th Log Rank
VT/VF 59.2 23.9 13.7 8.3
VT below detection rate 3.0 2.7 3.5 2.7
Recurrent VT below detection rate 11.8 12.5 26.6 —
VT below detection rate
NYHA I (N 5 142) 0.8 1.0 0 —
NYHA II 1 III (N 5 517) 3.6 3.2 4.8 — 0.021
Ejection fraction
.0.40 (N 5 320) 2.7 0.9 1.3 1.9
,0.40 (N 5 339) 3.3 3.7 6.2 3.8 0.027
Presenting spontaneous tachycardia
VF (N 5 330) 1.4 0.9 1.4 1.1
mVT (N 5 329) 4.7 4.6 5.9 4.9 ,0.001
No inducible mVT/inducible VF (N 5 293) 0.5 1.3 0.9 0
Inducible mVT (N 5 366) 4.0 3.7 5.3 4.6 ,0.001
No antiarrhythmic drug at discharge (N 5 419) 0.8 1.6 3.1 1.0
Beta-blocker (N 5 136) 3.3 3.2 2.8 4.2 NS
Amiodarone (N 5 41) 25.0 5.3 — — ,0.001
d-sotalol/dl-sotalol (N 5 46) 4.7 5.8 7.7 11.1 0.004
NYHA 5 New York Heart Association; mVT 5 monomorphic ventricular tachycardia; VF 5 ventricular fibrillation; VT 5 ventricular tachycardia.
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third and fourth year after ICD implantation in 281, 62, 20
and 12 patients with first VTs, respectively.
In NYHA class I, the risk of a VT below the detection
rate was below or equal to 1% per year during the first 4
years, whereas the risk in NYHA class II and III ranged
between 3.2% and 4.8% (p 5 0.021; Table 2). Patients with
EFs above 0.40 had a risk between 0.9% and 2.7% per year
during the first four years, as opposed to 3.3% to 6.2% in
patients with an EF below 0.40 (p 5 0.027; Table 2).
The risk of VTs above TDI ranged between 4.6% and
5.9% per year during the first four years in patients with
spontaneous monomorphic VTs, in contrast to 0.9% to
1.4% in patients without monomorphic VTs (Table 2; Fig.
2). Patients without inducible monomorphic VTs, patients
Figure 2. Risk of VTs above the programmed tachycardia detection interval and spontaneous ventricular tachycardias before ICD implantation. pres.
mVT 5 presenting monomorphic ventricular tachycardia.
Figure 3. Risk of VTs above the programmed tachycardia detection interval and inducible tachycardias. ind. MVT 5 inducible monomorphic VT; VF 5
ventricular fibrillation; VT 5 ventricular tachycardia.
561JACC Vol. 36, No. 2, 2000 Ba¨nsch et al.
August 2000:557–65 VTs Above Tachycardia Detection Interval
with inducible VF and polymorphic VTs included, had a
significantly lower risk to suffer a VT above TDI during the
first four years (0% to 1.3% per year during the first four
years) than patients with inducible monomorphic VTs
(3.7% to 5.3% per year, p , 0.001; Table 2, Fig. 3).
Of interest, there was no significant difference of the
induced VT CL between patients with (299 6 65 ms) and
without VTs (294 6 84 ms) above TDI. However, patients
with VTs above TDI showed a tendency for an increase of
CL from initial PVS to discharge PVS by 24 6 94 ms,
whereas patients without VTs above TDI rather showed a
decrease in induced VT CL by 20 6 71 ms (p 5 0.020,
Mann Whitney U test).
The risk of experiencing a VT above TDI was most
prominently related to the use of class III antiarrhythmic
drugs. Although all patients underwent PVS after any
change in antiarrhythmic medication and ICDs were pro-
grammed according to the results (in the case of amiodarone
PVS was performed after a loading phase), the risk of a VT
above TDI was 25% during the first year in patients on
amiodarone (p , 0.001 in comparison with patients without
antiarrhythmic drugs), and ranged between 4.7% and 11.1%
per year during the first four years after prescription of either
d- or d,l-sotalol (p 5 0.004 in comparison with patients on
no antiarrhythmic drugs (Table 2; Fig. 4).
Cox regression analysis revealed that amiodarone at
discharge increased the risk of a VT above TDI 1.7-fold
(p 5 0.022); patients with inducible monomorphic VTs had
a 2.7-fold increased risk and patients in NYHA class III had
a 1.5-fold increased risk to suffer a VT above the TDI
(Table 3). As expected, of these variables, only inducible
VTs (relative risk 1.5, p , 0.01) and prior heart failure also
predicted the recurrence of any VT.
However, the relative risk of a slow VT in patients with
recurrent VTs increased with the presence of risk predictors:
2 of 50 patients with recurrent VTs and no risk predictor
suffered a slow VT during follow-up (4%), 14 of 138 with
one risk predictor (10%), 22 of 151 with two risk predictors
(14%) and 8 of 36 with three risk predictors (22%) (Fig. 4).
Clinical significance. Only 7 VTs above TDI were asymp-
tomatic and were detected by chance in routine ECGs or
Holter ECGs during follow-up visits; 54 (88.5%) caused
clinical symptoms and admission to the hospital, 39 (63.9%)
caused palpitations or angina, 4 (6.6%) were associated with
cardiac decompensation, 5 (8.2%) caused syncope and
Figure 4. Risk of VTs above the initially programmed tachycardia detection interval and presence of risk predictors (inducible monomorphic VTs, NYHA
class II 1 III, amiodarone).
Table 3. Cox Regression Analysis for Major Events
VT Above TDI Symptomatic VT Above TDI any VT
Relative Risk Significance Relative Risk Significance Relative Risk p Value
Heart failure prior to ICD implantation 1.53 0.022 1.65 0.016 1.59 ,0.001
Inducible monomorphic VT 2.66 ,0.001 2.53 ,0.006 1.35 ,0.001
Amiodarone as discharge medication 1.69 0.036 1.80 0.011 20.03 NS
ICD 5 implantable cardioverter defibrillator; TDI 5 tachycardia detection interval; VT 5 ventricular tachycardia.
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during 6 VTs (9.8%) above TDI patients had to be
resuscitated.
Ventricular tachycardias above TDI that caused no symp-
toms and palpitation or angina were similar in CL (447 6
46.8 ms, range 400 to 520 ms, vs. 445 6 61 ms, range 330
to 550 ms). Ventricular tachycardias that were associated
with cardiac decompensation (CL 505 6 72 ms, range 330
to 550 ms) tended to be slower (NS). Ventricular tachycar-
dias that caused syncope (358 6 48 ms, range 340 to
460 ms) or cardiopulmonary resuscitation (CL 407 6
36 ms, range 350 to 450 ms) tended to be faster than
asymptomatic VTs (NS). All but one patient were success-
fully resuscitated, however, four died within one week of
resuscitation, three of end-stage heart failure and one with
intractable incessant VT.
Sixteen VTs above TDI (26.2%) terminated spontane-
ously, and nine VTs accelerated into the programmed
detection zone on hospital admission and thus required no
additional intervention. Thirty-six VTs above TDI required
external intervention: in 14 cases (23%), the detection rate
was decreased and the ICD terminated the VT automati-
cally, in two cases (3.3%), VTs were terminated with manual
overdrive stimulation via the ICD, 9 VTs (14.8%) were
terminated with intravenous antiarrhythmic drugs and 11
(18%) with external overdrive stimulation after intracardiac
placement of a stimulation catheter or external emergency
cardioversion.
Intervention to prevent recurrence. After all but three
VTs were above the TDI, the TDI was adjusted using a
safety margin of at least 30 ms. In three patients, the TDI
was not increased adequately, because the VT CL ranged
between 500 and 600 ms and was well tolerated (n 5 2) or
this VT was successfully treated with radiofrequency abla-
tion (n 5 1). In one patient without inducible or docu-
mented VTs before ICD implantation, a one-zone shock-
only device had to be replaced by a multi-zone device to
allow for antitachycardia pacing.
Despite an adjusted TDI, 9 of 47 patients had at least one
recurrent VT above TDI, 3 patients had at least two and 2
patients had three recurrences. The risk of recurrent VTs
above TDI was 11.8% during the first, 12.5% during the
second and 26.6% during the third year after first VT above
TDI. In all cases, a further increase in VT CL caused the
second VT above TDI. The CL of the first VT above TDI
was 424 6 52 ms and the CL of the second VT was 487 6
39 ms (p , 0.002).
If we had intended to address any VT of 50% of patients
with slow VTs, TDI would have to be increased to 25 to
27 ms, for 80%, TDI would have to be increased to 50 ms
and for 90%, by 90 to 100 ms.
DISCUSSION
In this large cohort of patients with ICDs, the risk of a VT
above TDI ranged between 2.7% and 3.5% per year and
remained constant over time. Impaired left ventricular
function, inducible and spontaneous monomorphic VTs
and class III antiarrhythmic drugs, especially amiodarone,
could be identified as independent risk predictors of a VT
above the initially programmed TDI. The first two risk
predictors also predicted any recurrent VT.
The occurrence of VTs above the TDI may be explained
in two ways. First, we may have documented the far end of
a distribution curve of spontaneous VT CLs, i.e., the 97th
percentile. The fact that the risk of a VT above the TDI
remained constant over time favors this “sampling error”
explanation. Second, a significant slowing of VTs occurs
over time with the use of class III antiarrhythmic drugs in
the setting of a high recurrence risk of VTs. If the
occurrence of VTs above the TDI was a matter of chance,
the probability of a recurrent VT above TDI should be less
than that of the initial VT, if the TDI was increased.
However, the risk of a recurrent VT increased to 0.12 per
year in spite of an increase in TDI. This favors the view that
at least in some patients a significant slowing of VTs
occurred. A look at individual patients with VTs above the
TDI revealed that in each case the VT above the TDI was
much slower than any VT spontaneous or induced earlier.
And the recurrent VT above the TDI was again slower than
the first in almost all cases (424 6 52 vs. 487 6 39 ms, p ,
0.002).
Patients without risk predictors. The risk of VTs above
TDI in patients after survived cardiac arrest without spon-
taneous or inducible monomorphic VTs and preserved left
ventricular function was below 1% per annum. Thus, the
current practice to program a TDI of 280 to 330 ms for the
detection interval in these patients seems to be adequate.
The risk of a monomorphic VT during follow-up has been
reported to be 18% in these patients during a follow-up of
14 months (18). This favors a two-zone device with the
possibility of antitachycardia pacing even in patients without
documented VTs.
Patients with risk predictors of VTs above the TDI.
Patients with single risk predictors presented with a 5% risk
to have a VT above the TDI during the first two years. This
risk is almost tripled in patients with all three risk predictors
and reaches 30% after four years.
The risk of a VT above TDI was significantly increased in
patients with spontaneous (4.6% to 5.9% per year) or
inducible (3.7% to 5.3% per year) monomorphic VTs. This
finding was most surprising because we expected that in
patients in whom we had information about spontaneous
tachycardias, the actual risk should have been lower. Of
interest, those patients with VTs above TDI did show a
trend to slower VTs during predischarge PVS. The opposite
was true for patients with VTs below the TDI.
VTs above TDI and heart failure. Most VTs above TDI
caused clinical symptoms and hospital admission (88.5%);
24.6% of VTs above TDI were even associated with
devastating events such as heart failure, syncope or cardio-
pulmonary resuscitation.
The association between cardiac decompensation and
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slowing of VTs may first be explained by a progressive
scarring of the myocardium, which again may cause slowing
of conduction (21–23).
Second, slow VTs caused cardiac arrest and heart failure
in some patients, although VTs were very slow (407 ms for
cardiac arrest, 505 ms for heart failure), because patients
with impaired left ventricular function often do not feel any
palpitations and VTs are not documented until these
patients are hospitalized for other symptoms such as angina
and heart failure. The fact that heart failure was reversible in
all but three patients favors this view.
Antiarrhythmic medication. Although all patients under-
went PVS in our clinic, if antiarrhythmic therapy was
changed (in case of amiodarone after a loading phase), to
detect an increase in defibrillation threshold and a slowing
of VTs above the TDI, the risk of VTs above the TDI was
significantly increased on amiodarone (25% during the first
year after initiation of therapy) or sotalol (4.7% to 11.1% per
year during the first four years) (24). This suggests an
increase of TDI after the initiation of antiarrythmic therapy
irrespective of EPS results.
Furthermore, the initiation of antiarryhthmic therapy
should be restricted to otherwise untractable patients with
many episodes that require shocks, because we may just
replace the problem of frequent tachycardias with the
problem of VTs above the TDI with significant clinical
impact. With the favorable results of radiofrequency abla-
tion both in patients with coronary artery disease, reported
by Strickberger et al. (25) and in patients with dilated
cardiomyopathy, reported by Kottkamp et al. (22), radio-
frequency ablation should always be considered first line
therapy.
Which TDI for which patient. Only 50% of the VTs
below the detection rate could have been detected if the
detection interval had been increased by 25 ms beyond the
usual 30 to 60 ms (7). Ninety percent detection would have
required an increase in detection interval by 87 ms, and a
95% detection would have made an increase of the TDI by
123 ms necessary. The need for a much larger safety margin
in some patients is in conflict with the fact that an increase
in TDI is strongly associated with inappropriate episodes.
Our report on the same cohort, published elsewere, revealed
that an increase of TDI by 10 beats/min increased the risk
of inappropriate episodes by 20% (26).
The clinical effects of the VTs above the TDI may
suggest an increase in TDI in patients who are prone to
highly symptomatic slow VTs. However, it is not yet clear
whether such slow VTs can be addressed by ICD therapy at
all with an acceptable risk of inadequate therapies and
whether this translates into a survival benefit.
Another solution to the dilemma between a mandatory
decrease of detection rate in patients with presenting or
inducible monomorphic VTs or on antiarrhythmic therapy
and the increasing risk of inappropriate episodes may be
detection algorithms, which allow for more independence
from detection rate. Such algorithms may include atrioven-
tricular dissociation (12–14) or QRS width (10,11) as
first-line detection criterion, especially in patients prone to
very slow VTs.
Conclusions and outlook. If the TDI of an ICD is
programmed as the CL of the slowest spontaneous or
inducible VT plus 30 to 60 ms, the risk of a VT below the
detection rate was about 3% per year. The risk of a recurrent
VT above the TDI ranged between 11% and 13% per year
during the first two years after the first VT above the TDI,
although the TDI was adapted to the slow VT.
The clinical effects of VTs above the TDI may suggests
an increase in TDI in selected patients. However, an
increase in TDI increases the risk of inappropriate therapies.
The questions whether slow VTs should be addressed by
ICDs at all and whether this is feasible with current ICD
technology have to be answered by a prospective trial, which
is underway: the “1112Trial.”
Study limitations. A retrospective analysis of VTs above
TDI is naturally based on reports of clinical emergencies.
Therefore, the number of VTs and the risk of VTs above
TDI may have been underestimated. Additionally, some
sudden deaths despite ICDs might be due to VTs above
TDI, as some of our patients with VTs above TDI had to
be resuscitated. Grubman et al. (27) reported that in 46% of
patients dying suddenly despite ICDs, no VT had been
recorded.
Supraventricular tachycardias with bundle-branch-block
morphology may have been erroneously taken for VTs.
However, ECGs were reviewed with care by at least two
cardiologists. If there were doubts about the ventricular
origin of the tachyarrhythmia, the episode was not supposed
to be of ventricular origin. Furthermore, atrial fibrillation
and sinus tachycardias during treadmill ECG, which we
have reported to be the strongest predictors and major
causes of inappropriate episodes, were not predictors of an
increased risk of VTs above TDI (Table 1). Therefore, we
assume that differentiation of VTs from other kinds of
episodes was sufficiently achieved (24).
Finally, all generations of ICDs were included in the
study. With current programming options, the detection
rate may be programmed less restrictively and the risk of
VTs above the TDI may be lower.
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